Generate Biomedicines, Inc. Common Stock · GENB

EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients. Dave Singh1, Kapil Mayawala2, Victoria Szenes2, Andreas Eich3, Brian Leaker4, Philipp Badorrek5, Stanislav Ignatenko6, Sacha Prashad2, Stephanie Straley2, Antonios Aliprantis7, Lovely Goyal2, Alex Synder2, Oliver Kornmann3 Affiliations: 1University of Manchester, Ma…

8-K · 2026-08-26 · 0001193125-26-365556

EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort …

8-K · 2026-08-06 · 0001193125-26-336462

EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (M…

8-K · 2026-05-07 · 0001193125-26-209899

Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.001 Generate: Biomedicines Certificate Number ZQ00000000 COMMON STOCK Shares * 000000 **** 000000 ******* ******* 000000 ********* ** 000000 ********* ****** 000000 * Generate Biomedicines, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT ** Mr. Alexander David Sample SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 370920 10 0 is the owner of **000000**Shares**** ***ZERO HUNDRED THOU…

S-1/A · 2026-02-13 · 0001193125-26-051761

Exhibit 4.3 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of May 9, 2023, by and among Generate Biomedicines, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (each of which is referred to in this Agreement as an “Investor”, and together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Subsection 6.9, the “In…

S-1/A · 2026-02-13 · 0001193125-26-051761

Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. WARRANT TO PURCHASE STOCK Corporation: …

S-1 · 2026-02-04 · 0001193125-26-037799